| Next 10 |
Ad
ATNF News and Press 180 Life Sciences Corp Com
News | 180 Life Sciences Corp Com (NASDAQ:ATNF)
-
2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...
-
2023-09-26 13:17:43 ET More on psychedelic drug development Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Qui...
-
2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...
-
2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...
-
2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...
-
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company, has closed on its previously announced public offering. The offering was comprised of 4,615,385 shares of the company’s common stock (or common stock equivalents in lieu thereof) as well as warrants to purchase up t...
-
PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the...
-
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company, announced the pricing of its current public offering. The offering consists of up to 4,615,385 shares of the company’s common stock and warrants for purchase at $0.65 per share. According to the announcement, the wa...
-
2023-08-10 09:15:50 ET 180 Life Sciences Corp ( NASDAQ: ATNF ) shares fell 21% on Thursday after it announced pricing of a public offering of 4,615,385 shares of company’s common stock and warrants to purchase up to 4,615,385 shares of common stock at purchase price per sha...
-
PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company’s commo...
Stock Information
180 Life Sciences Corp Com Company Name:
ATNF Stock Symbol:
NASDAQ Market:
Ad
-
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 111% to $0.4000. Avinger, Inc. (NASDAQ: AVGR) surged 63.2% to $6.75 amid the company announcing...
-
Gainers T2 Biosystems, Inc. (NASDAQ: TTOO) shares rose 44.4% to $0.4003 in pre-market trading. T2 Biosystems said it issued inducement awards to f...
-
Donald A. McGovern Jr., Board Member at 180 Life Sciences (NASDAQ:ATNF), reported a large acquisition of company stock options on September 6, acco...